You just read:

IsoPlexis Receives $1.8M National Cancer Institute Grant To Develop Automated Platform To Assess CAR-T Product Potency and Toxicity and Predict Patient Response

News provided by

IsoPlexis Corporation

Oct 23, 2017, 09:00 ET